Skip to content
Trial Eligibility
Menu

Clinical Trials Recruiting near Iowa City, IA

501 clinical trials have a recruiting site within 25 miles of Iowa City, Iowa, according to ClinicalTrials.gov data processed . The closest recruiting site is within 1 mile of the city center.

Distances are measured from the city center to each site's city, so they are approximate.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Studies enrolling near Iowa City

Showing 30 studies, nearest first.
  1. Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

    NCT03851445

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 25 mi
  2. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    NCT05174169

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 25 mi
  3. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

    NCT05812807

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 25 mi
  4. Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program

    NCT05008848

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  5. mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

    NCT05677490

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  6. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    NCT05879926

    • Phase 3
    • Ages 18 to 60 years
    • Sex: Female
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  7. Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

    NCT05929768

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  8. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    NCT06337318

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  9. Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

    NCT06418204

    • Observational
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  10. Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

    NCT06475989

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  11. Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

    NCT06532279

    • Phase 2
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  12. Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

    NCT06580314

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  13. Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

    NCT06661720

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  14. E-Mindfulness Approaches for Living After Breast Cancer

    NCT06748222

    • Phase 3
    • Ages 18 to 50 years
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  15. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    NCT06876714

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  16. Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

    NCT07061977

    • Phase 3
    • Ages 18 years and older
    • Sex: Female
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  17. Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

    NCT07198074

    • Phase 3
    • Ages 18 years and older
    • Sex: Female
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  18. Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

    NCT04817618

    • Phase 3
    • Ages 12 to 60 years
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 25 mi
  19. Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

    NCT05561387

    • Phase 3
    • Ages Any age
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 25 mi
  20. Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use

    NCT06489249

    • Early Phase 1
    • Ages 18 to 24 years
    • Sex: All
    • Accepts healthy volunteers
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 25 mi
  21. Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

    NCT06616584

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 25 mi
  22. Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

    NCT06712316

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 25 mi
  23. A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults

    NCT07768345

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 25 mi
  24. Follow-up Visit of High Risk Infants

    NCT00009633

    • Observational
    • Ages 18 to 26 months
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 25 mi
  25. Generic Database of Very Low Birth Weight Infants

    NCT00063063

    • Observational
    • Ages Up to 14 days
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 25 mi
  26. Fabry Disease Registry & Pregnancy Sub-registry

    NCT00196742

    • Observational
    • Ages Any age
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 25 mi
  27. Pompe Disease Registry Protocol

    NCT00231400

    • Observational
    • Ages Any age
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 25 mi
  28. Clinical Trial Readiness for the Dystroglycanopathies

    NCT00313677

    • Observational
    • Ages Any age
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 25 mi
  29. International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

    NCT00358943

    • Observational
    • Ages Any age
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 25 mi
  30. Pompe Pregnancy Sub-Registry

    NCT00567073

    • Observational
    • Ages Any age
    • Sex: Female
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 25 mi

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.